Portal de investigación
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A)
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Lassaletta, Alvaro
- Moreno, Lucas
- Ogawa, Chitose
- Ruggiero, Antonio
- Hoffman, Lindsey M.
- Pitou, Celine
- Zhou, Yanhong
- Hardebeck, Molly C.
- Knoderer, Holly
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Lassaletta,A,Moreno,L,Ogawa,C,Ruggiero,A,Hoffman,LM,Pitou,C,Zhou,Y et al. Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2023. Chicago. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2023.